Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, and its news flow centers on the development of two key product candidates: DA-1726 for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and vanoglipel (DA-1241) for MASH and type 2 diabetes. Company announcements frequently highlight clinical trial progress, new data readouts, and regulatory or listing updates that are relevant to investors and healthcare professionals following obesity and liver disease therapeutics.
News about DA-1726 includes Phase 1 multiple ascending dose results in obese but otherwise healthy adults, pharmacokinetic data supporting once-weekly subcutaneous dosing, and extended 8-week dosing cohorts at 48 mg. MetaVia has reported statistically significant weight loss, reductions in waist circumference, improvements in fasted glucose, and reductions in liver stiffness as measured by vibration-controlled transient elastography (VCTE), along with a favorable safety and tolerability profile. The company also releases updates on scientific presentations at meetings such as ObesityWeek, where DA-1726 data are shared with the medical community.
For vanoglipel (DA-1241), MetaVia’s news coverage includes Phase 2a trial results in presumed MASH patients, showing clinically meaningful reductions in glycated hemoglobin (HbA1c), improvements in liver inflammation and fibrosis markers, better liver steatosis and stiffness measures, and favorable shifts in plasma lipidomic profiles. The company announces poster presentations at major conferences such as the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, where detailed hepatic and metabolic data are presented.
In addition to clinical data, MetaVia issues news on corporate and capital market developments, including its 1-for-11 reverse stock split and communications regarding compliance with Nasdaq’s minimum bid price requirement. Readers of the MTVA news page can expect updates on trial milestones, conference presentations, research collaborations, and listing status, providing a consolidated view of MetaVia’s progress in cardiometabolic and liver disease drug development.
MetaVia (Nasdaq: MTVA) reported year-end 2025 results and a corporate update highlighting positive clinical progress and a tightened cash runway. DA-1726 48 mg Phase 1 showed ~9.1% weight loss, improved glucose control and reduced liver stiffness. IRB approval received for Part 3 titration study; dosing expected April 2026 with data in Q4 2026. Vanoglipel Phase 2a showed clinically meaningful metabolic and liver improvements. Cash and equivalents were $10.3M at year-end; January 2026 gross offering proceeds of ~$9.3M are expected to fund operations into Q4 2026.
MetaVia (Nasdaq: MTVA) received IRB approval to start Phase 1 Part 3 testing of DA-1726, a dual GLP-1/glucagon oxyntomodulin analog, in obese adults.
The 16-week cohorts (one-step to 48 mg; two-step to 64 mg) will enroll 40 subjects total, assess safety, PK/PD, metabolic and body-composition measures, with dosing starting in April and data expected in Q4 2026.
MetaVia (Nasdaq: MTVA) announced expanded global patent protection for vanoglipel (DA-1241), reporting 48 granted and pending patents across the U.S., Europe, Japan, China and other countries. The portfolio, exclusively licensed from Dong-A ST, covers the compound, manufacturing methods and therapeutic uses and provides protection into 2035, unless extended.
The patents target treatment applications for metabolic and liver diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and diabetes, and support MetaVia's strategy to maximize long-term value for vanoglipel.
MetaVia (Nasdaq: MTVA) announced that CEO Hyung Heon Kim will speak at the Life Sciences Virtual Investor Forum on March 12, 2026 at 10:30 am ET, discussing the company's pipeline of novel obesity and metabolic therapies.
The session is a live, interactive webcast with archived access available; one-on-one investor meetings and pre-registration are offered.
MetaVia (Nasdaq: MTVA) will present an update on its novel obesity and metabolic therapy pipeline at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET. Management will include CEO Hyung Heon Kim and CFO Marshall H. Woodworth and will take audience questions after the talk.
Investors can register for the virtual conference, submit questions in advance to questions@emerginggrowth.com, or schedule one-on-one meetings via mmiller@rxir.com.
MetaVia (Nasdaq: MTVA) announced a global intellectual property portfolio of 39 granted and pending patents for lead asset DA-1726, a long-acting dual GLP-1/glucagon oxyntomodulin analog, providing protection into 2041 unless extended.
MetaVia highlighted clinical results at 48 mg showing ~9% weight loss, waist and blood sugar improvements, early liver benefit, a favorable safety profile, and planned 16-week titration studies to 48 mg and 64 mg with results expected in Q4 2026.
MetaVia (Nasdaq: MTVA) reported positive AI-modeling results from its Syntekabio collaboration, where Syntekabio's DeepMatcher® platform identified inflammatory, cardiometabolic, and cancer-related target pathways for MetaVia's oral GPR119 agonist vanoglipel (DA-1241). The analysis supports MetaVia's focus on MASH and potential type 2 diabetes.
MetaVia noted its Phase 2a study in 109 patients over 16 weeks showed direct hepatic activity, improved glucose metabolism, and a favorable safety and tolerability profile. The company will continue AI-driven exploration to refine indications and optimize vanoglipel's therapeutic profile.
MetaVia (Nasdaq: MTVA) closed an underwritten public offering on Jan 16, 2026, raising approximately $9.3 million gross, which reflects full exercise of the underwriter's over-allotment option. The offering included 3,005,574 common shares (or equivalents), 4,508,361 Series C warrants (5-year, $3.10 exercise) and 4,508,361 Series D warrants (2-year, $3.10 exercise, callable after a positive Phase 1b Part III DA-1726 data readout). If all warrants and pre-funded warrants are exercised for cash, future gross proceeds could reach approximately $28.0 million. Net proceeds are intended for working capital and continued clinical development of DA-1726 for obesity.
MetaVia (Nasdaq: MTVA) reported positive Phase 1b results for DA-1726 from an 8-week non-titrated 48 mg cohort, showing early and statistically significant metabolic effects by Day 54.
Key results: weight -9.1% (21.2 lbs), waist -9.8 cm (p=0.022), fasted glucose -12.3 mg/dL, and liver stiffness -23.7% (VCTE); no treatment-related discontinuations and mainly mild-to-moderate GI events. The company plans 16-week titration studies with results expected in Q4 2026.
MetaVia (Nasdaq: MTVA) will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Company business development and clinical team members will attend the event scheduled for January 8–10, 2026 at the Chateaux Deer Valley in Park City, Utah.
This participation highlights MetaVia's engagement with the cardiometabolic and clinical research community but does not include financial or clinical readouts in this announcement.